Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 257 Carcinoma, Intraductal, Noninfiltrating 24 Breast Carcinoma In Situ 21 Neoplasms 12 Neoplasm Metastasis 12 Breast Neoplasms, Male 12 Ovarian Neoplasms 10 Inflammatory Breast Neoplasms 7 Glioblastoma 6 Prostatic Neoplasms 5 Endometrial Neoplasms 5 Central Nervous System Neoplasms 5 Gliosarcoma 4 Fallopian Tube Neoplasms 4 Breast Cancer Female 4 Brain Neoplasms 4 Glioma 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Breast Diseases 3 Astrocytoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma 2 Recurrence 2 Pancreatic Neoplasms 2 Oligodendroglioma 2 Medulloblastoma 2 Liver Neoplasms 2 Infertility 2

Interventions

Fulvestrant 6 Letrozole 4 exemestane 3 dalpiciclib 3 Trastuzumab 3 Docetaxel 3 Capecitabine 3 Anastrozole 3 ribociclib 2 palbociclib 2 fluzoparib 2 apatinib 2 Irinotecan 2 Gemcitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 sacituzumab govitecan 1 pyrotinib 1 pegfilgrastim 1 patritumab deruxtecan 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Tamoxifen 1 Rogaratinib 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Cancer Metastatic × Tamoxifen × Clear all

NCT04059484 2026-02-24

AMEERA-3

Sanofi

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡